2026 · 2nd Quarter (Apr 1 - June 30)

AGIOS PHARMACEUTICALS

Filed by GRIDIRON PUBLIC AFFAIRS, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 17, 2026
Income: $10,000.00
Expenses: Not reported
Registrant: GRIDIRON PUBLIC AFFAIRS, LLC
Client: AGIOS PHARMACEUTICALS
Filing UUID: 7d89163a-bddc-4543-9cd1-0c3bb80b831b
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs

Literal federal measure citations: H.R. 5187, H.R. 5094

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.